- Report
- April 2025
- 194 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 179 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 283 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 194 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 208 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 88 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- January 2025
- 250 Pages
Global
From €4550EUR$4,999USD£3,900GBP
- Report
- April 2024
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Book
- April 2020
- 336 Pages
- Book
- April 2019
- 816 Pages
- Book
- July 2018
- 832 Pages
- Book
- October 2015
- 520 Pages
- Book
- March 2015
- 352 Pages
- Book
- October 2013
- 624 Pages
- Book
- October 2012
- 456 Pages
- Book
- April 2012
- 1272 Pages
- Book
- May 2009
- 354 Pages
- Book
- February 2020
- 1152 Pages

Cirrhosis is a condition in which the liver becomes scarred and unable to function properly. It is a common complication of chronic liver diseases such as hepatitis, alcohol abuse, and fatty liver disease. Symptoms of cirrhosis include jaundice, fatigue, abdominal pain, and fluid buildup in the abdomen. Treatment for cirrhosis includes lifestyle changes, medications, and in some cases, liver transplantation.
The cirrhosis market is a subset of the hepatology market, which focuses on the diagnosis and treatment of liver diseases. The cirrhosis market is composed of pharmaceuticals, biologics, and medical devices used to treat cirrhosis. These products are used to reduce symptoms, slow the progression of the disease, and improve quality of life.
Companies in the cirrhosis market include AbbVie, Gilead Sciences, Merck, Novartis, and Pfizer. Show Less Read more